Pyxis Oncology Inc (NASDAQ:PYXS) shares, rose in value on Wednesday, June 18, with the stock price down by -4.20% to the previous day’s close as strong demand from buyers drove the stock to $1.14.
Actively observing the price movement in the last trading, the stock closed the session at $1.19, falling within a range of $1.135 and $1.215. The value of beta (5-year monthly) was 1.18. Referring to stock’s 52-week performance, its high was $5.39, and the low was $0.83. On the whole, PYXS has fluctuated by -7.32% over the past month.
With the market capitalization of Pyxis Oncology Inc currently standing at about $70.62 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-15.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PYXS’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PYXS currently trading nearly -8.14% and 0.38% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.55, while the 7-day volatility ratio is showing 2.09% which for the 30-day chart, stands at 4.04%. Furthermore, Pyxis Oncology Inc (PYXS)’s beta value is 1.18, and its average true range (ATR) is 0.08.
A comparison of Pyxis Oncology Inc (PYXS) with its peers suggests the former has fared considerably weaker in the market. PYXS showed an intraday change of -4.20% in last session, and over the past year, it shrunk by -69.92%%.
Data on historical trading for Pyxis Oncology Inc (NASDAQ:PYXS) indicates that the trading volumes over the past 10 days have averaged 0.42 and over the past 3 months, they’ve averaged 475.84K. According to company’s latest data on outstanding shares, there are 61.63 million shares outstanding.
Nearly 28.94% of Pyxis Oncology Inc’s shares belong to company insiders and institutional investors own 37.56% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.47 million shares as on 2025-05-30, resulting in a short ratio of 14.49. According to the data, the short interest in Pyxis Oncology Inc (PYXS) stood at 1265.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 7.23 million. The stock has fallen by -26.92% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PYXS stock heading into the next quarter.
